| Similar Articles |
|---|
 |
Fast Company
August 2005
Jennifer Reingold |
CEO See-Ya! With governance specialists Glass, Lewis & Co., we propose Maytag's Ralph Hake as this month's candidate for spring cleaning.   |
Fast Company
January 2004
Jennifer Reingold |
CEO See-Ya! Which CEOs deserve the boot? This month's candidate is Great Lakes Chemical Corp.'s CEO, Mark P. Bulriss. |
The Motley Fool
July 20, 2006
Brian Lawler |
MedImmune Is Easy to Resist Despite the prospects from sales of two new vaccines, it's hard to feel better about this stock. |
The Motley Fool
April 11, 2007
Brian Lawler |
MedImmune Brings Home the Bacon The drugmaker announces preliminary first-quarter financial results. |
The Motley Fool
October 30, 2006
Brian Lawler |
MedImmune's Mediocre Quarter Some patient folks may be willing to wait on MedImmune to turn things around and justify its high valuation, but most other investors should be able to find better value elsewhere in the biotech industry. |
BusinessWeek
March 29, 2004
Gene G. Marcial |
Recovery At MedImmune? Flu season is over, but it was a disaster for the No. 6 U.S. biotech, MedImmune (MEDI ). Its ballyhooed FluMist, a nasal-spray flu vaccine, was a flop -- which sent the stock reeling, from 42 in June to 23 now. As a result, some pros are buying: David Katz of Matrix Asset Advisors is confident MedImmune can turn FluMist around, by pricing it lower and educating doctors and consumers about the product. |
The Motley Fool
April 24, 2007
Brian Lawler |
MedImmune Not Immune to Takeovers MedImmune shops itself to AstraZeneca. MedImmune investors appear to be getting a pretty sweet deal. |
The Motley Fool
October 14, 2010
Sean Williams |
Should You Let AstraZeneca Go? Multiple drug patent expirations await. It's time to run away. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: MedImmune Will the years ahead continue to be positive for the biopharma? Next year's guidance is for revenue to grow 15% over the $1.3 billion that is expected in 2006. Investors should watch to make sure this is possible. |
The Motley Fool
March 1, 2004
Alyce Lomax |
MedImmune Under the Weather After short-term setbacks, the biotech turns to the long term. |
The Motley Fool
May 30, 2007
Brian Orelli |
MedImmune's FDA Roller Coaster The vaccine maker is having its share of ups and downs, courtesy of the FDA. Investors, take note. |
The Motley Fool
April 21, 2005
Charly Travers |
Synagis Has Some Legs Left The mature drug still generates big numbers for MedImmune. Investors, take note. |
The Motley Fool
July 22, 2004
Charly Travers |
Patience With MedImmune While MedImmune has one of the top-selling biologic drugs in the industry, the growth in revenues and earnings is a bit sluggish for what many biotech investors are looking for. |
The Motley Fool
June 16, 2004
Alyce Lomax |
It's Half-Time at MedImmune The company will slash the price of FluMist. |
CIO
March 1, 2002
Ben Worthen |
Travelin' Man A profile of Randy Mott, CIO of Dell Computer... |
The Motley Fool
April 13, 2007
Brian Lawler |
MedImmune Wants a Mate The biopharma announces the hiring of investment bankers to look for a possible acquirer. Investors, take note. |
The Motley Fool
April 29, 2004
Charly Travers |
MedImmune's Big Gamble FluMist may not be worth the gigantic R&D investment. |
The Motley Fool
January 13, 2004
Alyce Lomax |
MedImmune's Sticker Shock Price cut for FluMist is reportedly in the works. |
The Motley Fool
January 16, 2007
Brian Lawler |
MedImmune's Improved Flu Vaccine One of the three most important traits for a drug's success is convenience in dosing, so investors should be mindful of the FDA's actions on FluMist, MedImmune's nasal spray vaccine, in the coming months. |
The Motley Fool
April 12, 2004
Charly Travers |
Bargain Hunting in Big Biotech MedImmune's recent FluMist troubles may have created a buying opportunity for long-term investors. |
The Motley Fool
May 17, 2007
Brian Lawler |
MedImmune Gets the Thumbs-Up An advisory panel recommends expanded use for one of MedImmune's drugs. |
Bio-IT World
December 15, 2003
Kline & Greenhalgh |
When Patents Persist What if that patent you're paying royalties on suddenly gets extended? Have you negotiated the best licensing deal possible? |
BusinessWeek
January 15, 2007
Gene G. Marcial |
A Buyer For MedImmune? The crowd prodding MedImmune to put itself on the block is apt to get bigger - even though the seventh-largest U.S. biotech has rejected such a move. |
